# QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy

> **NCT03387098** · PHASE1,PHASE2 · TERMINATED · sponsor: **ImmunityBio, Inc.** · enrollment: 4 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Aldoxorubicin HCl
- **BIOLOGICAL:** ALT-803
- **BIOLOGICAL:** ETBX-011
- **BIOLOGICAL:** GI-4000
- **BIOLOGICAL:** haNK for infusion
- **BIOLOGICAL:** avelumab
- **BIOLOGICAL:** bevacizumab
- **DRUG:** Capecitabine
- **DRUG:** Cyclophosphamide
- **DRUG:** Fluorouracil
- **DRUG:** Leucovorin
- **DRUG:** nab-Paclitaxel
- **DRUG:** lovaza
- **DRUG:** Oxaliplatin
- **PROCEDURE:** SBRT

## Key facts

- **NCT ID:** NCT03387098
- **Lead sponsor:** ImmunityBio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-12-28
- **Primary completion:** 2018-09-12
- **Final completion:** 2019-01-15
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention
- **Last updated:** 2024-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03387098

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03387098, "QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03387098. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*